Skip to main content
. 2022 Jun 12;37(9):2175–2185. doi: 10.1093/humrep/deac137

Table II.

Baseline characteristics of women in menopausal hormone therapy (MHT) users and MHT non-users.

MHT users MHT non-users Chi-squared value
(n = 86 980) (n = 91 024)
Year of birth
<1940 3845 (4.4%) 3669 (4.0%) χ2 = 6892.8, df =3
1940–1949 56 788 (65.3%) 42 389 (46.6%)
1950–1959 23 820 (27.4%) 40 099 (44.1%)
≥1960 2527 (2.9%) 4867 (5.4%)
Race/ethnicity
Caucasian 84 715 (97.4%) 86 095 (94.6%) χ2 = 962.9, df =3
Asian 987 (1.1%) 2263 (2.5%)
Black 751 (0.9%) 1900 (2.1%)
Others 527 (0.6%) 766 (0.8%)
BMI (kg/m2)
Underweight, <18.5 495 (0.6%) 781 (0.9%) χ2 = 219.0, df =3
Normal, 18.5–24.9 30 942 (35.7%) 34 718 (38.3%)
Overweight, 25.0–29.9 34 346 (39.6%) 33 456 (36.9%)
Obese, ≥30 20 853 (24.1%) 21 663 (23.9%)
Smoking status
Never 46 620 (53.8%) 56 583 (62.4%) χ2 = 1342.7, df =2
Past 32 176 (37.1%) 27 131 (29.9%)
Present 7838 (9.1%) 7015 (7.7%)
Years of education
≤10 years 48 603 (56.1%) 45 368 (50.0%) χ2 = 653.5, df =2
11–12 years 9475 (10.9%) 11 252 (12.4%)
>12 years 28 573 (33.0%) 34 062 (37.6%)
Age at menarche
≤11 18 492 (21.7%) 17 640 (19.9%) χ2 = 115.8, df =4
12 15 982 (18.7%) 17 127 (19.3%)
13 19 876 (23.3%) 21 948 (24.7%)
14 16 662 (19.5%) 17 537 (19.7%)
≥15 14 280 (16.7%) 14 585 (16.4%)
Parity
0 13 102 (15.1%) 16 187 (17.8%) χ2 = 241.8, df =3
1 11 100 (12.8%) 11 333 (12.5%)
2 40 324 (46.4%) 40 565 (44.6%)
≥3 22 405 (25.8%) 22 877 (25.2%)
Family history of CVD #
Yes 53 802 (63.0%) 53 454 (59.7%) χ2 = 201.7, df =1
No 31 569 (37.0%) 36 065 (40.3%)
Family history of breast cancer
Yes 6050 (7.2%) 7731 (8.7%) χ2 = 144.2, df =1
No 78 498 (92.8%) 80 953 (91.3%)
Family history of lung cancer
Yes 11 287 (13.2%) 10 762 (12.0%) χ2 = 57.0, df =1
No 74 084 (86.8%) 78 757 (88.0%)
Family history of colorectal cancer
Yes 9002 (10.5%) 8757 (9.8%) χ2 = 27.8, df =1
No 76 369 (89.5%) 80 762 (90.2%)

All P-values were <0.001.

#

Cardiovascular diseases, including coronary heart disease and stroke.